中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 9
Sep.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(9): 2229-2235

Immunoregulatory effect of fatty acid metabolic reprogramming in hepatocellular carcinoma and targeted therapeutic strategies

DOI: 10.12449/JCH260931
  • 1.

    Department of Hepatology，The First Hospital of Jilin University，Changchun 130021，China

  • 2.

    General Surgery Center，The First Hospital of Jilin University，Changchun 130021，China

Research funding:

Leizhou City Medical and Health Public Service Strengths and Weaknesses Research Project (3R2241120428)

More Information
  • Corresponding author: Ji Huifan， jihf@jlu.edu.cn （ORCID： 0000-0001-8816-1906）; Gao Yanhang， yanhang@mail.jlu.edu.cn （ORCID： 0000-0001-8590-6706）
  • Received Date: 2025-12-31
  • Accepted Date: 2026-03-09
  • Published Date: 2026-09-25
    Abstract
  • Metabolic reprogramming is a key characteristic of hepatocellular carcinoma， and abnormal fatty acid metabolism is closely associated with tumor immune escape. This article systematically reviews the molecular mechanisms of fatty acid metabolic reprogramming in hepatocellular carcinoma， focusing on key enzymes and their transcriptional regulatory networks within de novo lipogenesis and fatty acid oxidation pathways. This article also analyzes the metabolic heterogeneity between β-catenin-mutant hepatocellular carcinoma and AXIN1-mutant hepatocellular carcinoma and their therapeutic implications， summarizes the multidimensional mechanisms by which the lipid microenvironment regulates immune cell function， and reviews the targeted therapeutic strategies for different molecular subtypes of hepatocellular carcinoma.

     

    • FullText(HTML)
  • loading
    • References(44)
  • [1]
    Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74( 3): 229- 263. DOI: 10.3322/caac.21834.
    [2]
    Hanahan D. Hallmarks of cancer: New dimensions[J]. Cancer Discov, 2022, 12( 1): 31- 46. DOI: 10.1158/2159-8290.cd-21-1059.
    [3]
    An L B, Li Z F. Molecular network of metabolic reprogramming and precision diagnosis and treatment of hepatocellular carcinoma[J]. Biomark Res, 2025, 13( 1): 124. DOI: 10.1186/s40364-025-00844-5.
    [4]
    Xia L Z, Oyang L, Lin J G, et al. The cancer metabolic reprogramming and immune response[J]. Mol Cancer, 2021, 20( 1): 28. DOI: 10.1186/s12943-021-01316-8.
    [5]
    Senni N, Savall M, Cabrerizo Granados D, et al. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids[J]. Gut, 2019, 68( 2): 322- 334. DOI: 10.1136/gutjnl-2017-315448.
    [6]
    Li L, Zhang XJ, Xu G, et al. Transcriptional regulation of de novo lipogenesis by SIX1 in liver cancer cells[J]. Adv Sci, 2024, 11( 41): 2404229. DOI: 10.1002/advs.202404229.
    [7]
    Calvisi D F, Wang C M, Ho C, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma[J]. Gastroenterology, 2011, 140( 3): 1071- 1083. DOI: 10.1053/j.gastro.2010.12.006.
    [8]
    Pérez-Díaz A J, Núñez-Sánchez M Á, Ramos-Molina B. Revisiting liver metabolism through acetyl-CoA carboxylase inhibition[J]. Trends Endocrinol Metab, 2024, 35( 7): 563- 565. DOI: 10.1016/j.tem.2024.04.010.
    [9]
    Huang J, Tsang W Y, Fang X N, et al. FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma[J]. Cancer Res, 2024, 84( 6): 855- 871. DOI: 10.1158/0008-5472.can-23-0966.
    [10]
    Li Y, Yang W J, Zheng Y Y, et al. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis[J]. J Exp Clin Cancer Res, 2023, 42( 1): 6. DOI: 10.1186/s13046-022-02567-z.
    [11]
    Liu H H, Xu Y, Li C J, et al. An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming[J]. Mol Ther, 2022, 30( 7): 2554- 2567. DOI: 10.1016/j.ymthe.2022.03.015.
    [12]
    Lehrich B M, Monga S P. WNT-β-catenin signalling in hepatocellular carcinoma: From bench to clinical trials[J]. Nat Rev Gastroenterol Hepatol, 2026, 23( 3): 246- 263. DOI: 10.1038/s41575-025-01127-y.
    [13]
    Calle R A, Amin N B, Carvajal-Gonzalez S, et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials[J]. Nat Med, 2021, 27( 10): 1836- 1848. DOI: 10.1038/s41591-021-01489-1.
    [14]
    Benichou E, Seffou B, Topçu S, et al. The transcription factor ChREBP Orchestrates liver carcinogenesis by coordinating the PI3K/AKT signaling and cancer metabolism[J]. Nat Commun, 2024, 15: 1879. DOI: 10.1038/s41467-024-45548-w.
    [15]
    Chen J R, Ding C F, Chen Y H, et al. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway[J]. Cancer Lett, 2021, 502: 154- 165. DOI: 10.1016/j.canlet.2020.12.019.
    [16]
    Li J B, Huang Q C, Long X Y, et al. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways[J]. J Hepatol, 2015, 63( 6): 1378- 1389. DOI: 10.1016/j.jhep.2015.07.039.
    [17]
    Ma K, Chu J H, Liu Y F, et al. Hepatocellular carcinoma LINC01116 outcompetes T cells for linoleic acid and accelerates tumor progression[J]. Adv Sci, 2024, 11( 21): 2400676. DOI: 10.1002/advs.202400676.
    [18]
    Qin Y F, Huo F, Feng Z, et al. CD36 promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage hepatocellular carcinoma[J]. Clin Mol Hepatol, 2025, 31( 3): 960- 980. DOI: 10.3350/cmh.2024.0948.
    [19]
    Wabitsch S, Mccallen J D, Kamenyeva O, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD[J]. J Hepatol, 2022, 77( 3): 748- 760. DOI: 10.1016/j.jhep.2022.03.010.
    [20]
    Gu M, Zhang Y, Lin Z J, et al. Decrease in UCP1 by sustained high lipid promotes NK cell necroptosis to exacerbate nonalcoholic liver fibrosis[J]. Cell Death Dis, 2024, 15: 518. DOI: 10.1038/s41419-024-06910-4.
    [21]
    Qin W H, Yang Z S, Li M, et al. High serum levels of cholesterol increase antitumor functions of nature killer cells and reduce growth of liver tumors in mice[J]. Gastroenterology, 2020, 158( 6): 1713- 1727. DOI: 10.1053/j.gastro.2020.01.028.
    [22]
    Wang Y C, Chen W B, Qiao S, et al. Lipid droplet accumulation mediates macrophage survival and Treg recruitment via the CCL20/CCR6 axis in human hepatocellular carcinoma[J]. Cell Mol Immunol, 2024, 21( 10): 1120- 1130. DOI: 10.1038/s41423-024-01199-x.
    [23]
    Huang J J, Pan H Y, Sun J, et al. TMEM147 aggravates the progression of HCC by modulating cholesterol homeostasis, suppressing ferroptosis, and promoting the M2 polarization of tumor-associated macrophages[J]. J Exp Clin Cancer Res, 2023, 42( 1): 286. DOI: 10.1186/s13046-023-02865-0.
    [24]
    Veglia F, Sanseviero E, Gabrilovich D I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity[J]. Nat Rev Immunol, 2021, 21( 8): 485- 498. DOI: 10.1038/s41577-020-00490-y.
    [25]
    Li C X, Xiong L T, Yang Y H, et al. Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation[J]. Mol Cancer, 2025, 24( 1): 34. DOI: 10.1186/s12943-025-02238-5.
    [26]
    Santos P M, Menk A V, Shi J, et al. Tumor-derived α-fetoprotein suppresses fatty acid metabolism and oxidative phosphorylation in dendritic cells[J]. Cancer Immunol Res, 2019, 7( 6): 1001- 1012. DOI: 10.1158/2326-6066.cir-18-0513.
    [27]
    Ma C H, Wang S Y, Dong B N, et al. Metabolic reprogramming of immune cells in MASH[J]. Hepatology, 2025. DOI: 10.1097/hep.0000000000001371.
    [28]
    Pfister D, Núñez N G, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC[J]. Nature, 2021, 592( 7854): 450- 456. DOI: 10.1038/s41586-021-03362-0.
    [29]
    Yuan Y, Li P Y, Li J H, et al. Protein lipidation in health and disease: Molecular basis, physiological function and pathological implication[J]. Signal Transduct Target Ther, 2024, 9: 60. DOI: 10.1038/s41392-024-01759-7.
    [30]
    Yao H, Lan J, Li C S, et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours[J]. Nat Biomed Eng, 2019, 3( 4): 306- 317. DOI: 10.1038/s41551-019-0375-6.
    [31]
    Wang J, Hao J W, Wang X, et al. DHHC4 and DHHC5 facilitate fatty acid uptake by palmitoylating and targeting CD36 to the plasma membrane[J]. Cell Rep, 2019, 26( 1): 209- 221. DOI: 10.1016/j.celrep.2018.12.022.
    [32]
    Santiso A, Heinemann A, Kargl J. Prostaglandin E2 in the tumor microenvironment, a convoluted affair mediated by EP receptors 2 and 4[J]. Pharmacol Rev, 2024, 76( 3): 388- 413. DOI: 10.1124/pharmrev.123.000901.
    [33]
    Zhao Z B, Liu X Y, Xiang Y, et al. Inhibiting cholesterol de novo synthesis promotes hepatocellular carcinoma progression by upregulating prostaglandin E synthase 2-mediated arachidonic acid metabolism under high fatty acid conditions[J]. Cancer Sci, 2024, 115( 2): 477- 489. DOI: 10.1111/cas.16035.
    [34]
    Morotti M, Grimm A J, Hope H C, et al. PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function[J]. Nature, 2024, 629( 8011): 426- 434. DOI: 10.1038/s41586-024-07352-w.
    [35]
    Pedde A M, Kim H, Donakonda S, et al. Tissue-colonizing disseminated tumor cells secrete prostaglandin E2 to promote NK cell dysfunction and evade anti-metastatic immunity[J]. Cell Rep, 2024, 43( 11): 114855. DOI: 10.1016/j.celrep.2024.114855.
    [36]
    Veglia F, Tyurin V A, Blasi M, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer[J]. Nature, 2019, 569( 7754): 73- 78. DOI: 10.1038/s41586-019-1118-2.
    [37]
    Lally J S V, Ghoshal S, Deperalta D K, et al. Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma[J]. Cell Metab, 2019, 29( 1): 174- 182. DOI: 10.1016/j.cmet.2018.08.020.
    [38]
    Loomba R, Mohseni R, Lucas K J, et al. TVB-2640(FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial[J]. Gastroenterology, 2021, 161( 5): 1475- 1486. DOI: 10.1053/j.gastro.2021.07.025.
    [39]
    Lin Y Z, Ruze R, Zhang R Q, et al. Immunometabolic targets in CD8+ T cells within the tumor microenvironment of hepatocellular carcinoma[J]. Liver Cancer, 2024, 14( 4): 474- 496. DOI: 10.1159/000542578.
    [40]
    Take Y, Koizumi S, Nagahisa A. Prostaglandin E receptor 4 antagonist in cancer immunotherapy: Mechanisms of action[J]. Front Immunol, 2020, 11: 324. DOI: 10.3389/fimmu.2020.00324.
    [41]
    Zhu G Q, Tang Z, Huang R, et al. CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor[J]. Cell Discov, 2023, 9: 25. DOI: 10.1038/s41421-023-00529-z.
    [42]
    Tzeng S F, Yu Y R, Park J, et al. PLT012, a humanized CD36-blocking antibody, is effective for unleashing antitumor immunity against liver cancer and liver metastasis[J]. Cancer Discov, 2025, 15( 8): 1676- 1696. DOI: 10.1158/2159-8290.cd-24-1409.
    [43]
    Harding J J, Nandakumar S, Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies[J]. Clin Cancer Res, 2019, 25( 7): 2116- 2126. DOI: 10.1158/1078-0432.ccr-18-2293.
    [44]
    O’sullivan D, Sanin D E, Pearce E J, et al. Metabolic interventions in the immune response to cancer[J]. Nat Rev Immunol, 2019, 19( 5): 324- 335. DOI: 10.1038/s41577-019-0140-9.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (87) PDF downloads(9) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return